Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials.

Welzel, Tatjana; Winskill, Carolyn; Zhang, Nancy; Woerner, Andreas; Pfister, Marc

Welzel, Tatjana; Winskill, Carolyn; Zhang, Nancy; Woerner, Andreas; Pfister, Marc.

Afiliação

Welzel T; Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel (UKBB), University of Basel, Spitalstrasse 33, CH 4031, Basel, Switzerland. Tatjana.Welzel@ukbb.ch.
Winskill C; Paediatric Rheumatology, University Children's Hospital Basel (UKBB), University of Basel, Basel, Switzerland. Tatjana.Welzel@ukbb.ch.
Zhang N; Integrated Drug Development, Certara LP, Princeton, NJ, USA.
Woerner A; Integrated Drug Development, Certara LP, Princeton, NJ, USA.
Pfister M; Paediatric Rheumatology, University Children's Hospital Basel (UKBB), University of Basel, Basel, Switzerland.

Pediatr Rheumatol Online J ; 19(1): 46, 2021 Mar 25.

Article em En | MEDLINE | ID: mdl-33766063

Assuntos

Antirreumáticos/uso terapêutico; Inibidores de Janus Quinases/uso terapêutico; Doenças Reumáticas/tratamento farmacológico; Criança; Humanos; Ensaios Clínicos Controlados Aleatórios como Assunto

Palavras-chave

Efficacy; Monoclonal antibodies; Paediatric rheumatology; Pharmacokinetics; Randomized controlled trials; Safety

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Reumáticas / Antirreumáticos / Inibidores de Janus Quinases Tipo de estudo: Clinical_trials / Prognostic_studies / Systematic_reviews Limite: Child / Humans Idioma: En Revista: Pediatr Rheumatol Online J Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suíça

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google